ARS Pharmaceuticals
SPRY
About: ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Employees: 167
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
175% more call options, than puts
Call options by funds: $11.1M | Put options by funds: $4.05M
167% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 8 (+5) [Q2]
74% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 47
54% more capital invested
Capital invested by funds: $960M [Q1] → $1.48B (+$516M) [Q2]
18% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 22
8.33% more ownership
Funds ownership: 77.73% [Q1] → 86.07% (+8.33%) [Q2]
1% more funds holding
Funds holding: 184 [Q1] → 186 (+2) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
|
Roth Capital
Jason Wittes
|
$40
|
Buy
Initiated
|
4 Sep 2025 |
Financial journalist opinion
Based on 3 articles about SPRY published over the past 30 days
